ATE231494T1 - Chinazoline als chemotherapeutika - Google Patents
Chinazoline als chemotherapeutikaInfo
- Publication number
- ATE231494T1 ATE231494T1 AT98202103T AT98202103T ATE231494T1 AT E231494 T1 ATE231494 T1 AT E231494T1 AT 98202103 T AT98202103 T AT 98202103T AT 98202103 T AT98202103 T AT 98202103T AT E231494 T1 ATE231494 T1 AT E231494T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- aralkyl
- benzyl
- phenyl
- alkyl
- Prior art date
Links
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 title 1
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 abstract 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 230000003389 potentiating effect Effects 0.000 abstract 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 2
- 102000011724 DNA Repair Enzymes Human genes 0.000 abstract 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 abstract 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 abstract 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C247/00—Compounds containing azido groups
- C07C247/16—Compounds containing azido groups with azido groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Radiation-Therapy Devices (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9404485A GB9404485D0 (en) | 1994-03-09 | 1994-03-09 | Benzamide analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE231494T1 true ATE231494T1 (de) | 2003-02-15 |
Family
ID=10751492
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98202103T ATE231494T1 (de) | 1994-03-09 | 1995-03-09 | Chinazoline als chemotherapeutika |
| AT95910653T ATE184271T1 (de) | 1994-03-09 | 1995-03-09 | Analoge von benzamid, zur verwendung als parp(adp-ribosyltransferase, adprt) dns- reparaturenzyminhibitoren |
| AT98202102T ATE210651T1 (de) | 1994-03-09 | 1995-03-09 | Benzamidanaloga zur verwendung als parp- (adp- ribosyltransferase, adprt) dns-reparaturenzym inhibitoren |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95910653T ATE184271T1 (de) | 1994-03-09 | 1995-03-09 | Analoge von benzamid, zur verwendung als parp(adp-ribosyltransferase, adprt) dns- reparaturenzyminhibitoren |
| AT98202102T ATE210651T1 (de) | 1994-03-09 | 1995-03-09 | Benzamidanaloga zur verwendung als parp- (adp- ribosyltransferase, adprt) dns-reparaturenzym inhibitoren |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US5756510A (de) |
| EP (3) | EP0749415B1 (de) |
| JP (1) | JPH09510704A (de) |
| CN (1) | CN1081624C (de) |
| AT (3) | ATE231494T1 (de) |
| CA (1) | CA2184747C (de) |
| DE (3) | DE69524641T2 (de) |
| DK (2) | DK0879820T3 (de) |
| ES (2) | ES2135707T3 (de) |
| GB (1) | GB9404485D0 (de) |
| GR (1) | GR3031886T3 (de) |
| PT (1) | PT879820E (de) |
| WO (1) | WO1995024379A1 (de) |
Families Citing this family (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6372770B1 (en) | 1994-10-12 | 2002-04-16 | Euro-Celtique, S.A. | Benzoxazoles |
| US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
| AU1743997A (en) * | 1996-12-20 | 1998-07-17 | Geron Corporation | Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescence |
| GB9702701D0 (en) * | 1997-02-01 | 1997-04-02 | Univ Newcastle Ventures Ltd | Quinazolinone compounds |
| DE19726824C1 (de) * | 1997-06-24 | 1999-03-04 | Deutsches Krebsforsch | Verfahren zur Identifizierung kanzerogener Agenzien |
| AU9298098A (en) * | 1997-09-03 | 1999-03-22 | Guilford Pharmaceuticals Inc. | Amino-substituted compounds, methods, and compositions for inhibiting parp activity |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| US6235748B1 (en) | 1997-09-03 | 2001-05-22 | Guilford Pharmaceuticals Inc. | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6197785B1 (en) * | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
| US6426415B1 (en) | 1997-09-03 | 2002-07-30 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods and compositions for inhibiting parp activity |
| US6514983B1 (en) | 1997-09-03 | 2003-02-04 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage |
| US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6346536B1 (en) | 1997-09-03 | 2002-02-12 | Guilford Pharmaceuticals Inc. | Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same |
| US20020028813A1 (en) * | 1997-09-03 | 2002-03-07 | Paul F. Jackson | Thioalkyl compounds, methods, and compositions for inhibiting parp activity |
| US6635642B1 (en) * | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| WO1999011644A1 (en) * | 1997-09-03 | 1999-03-11 | Guilford Pharmaceuticals Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
| US6121278A (en) * | 1997-09-03 | 2000-09-19 | Guilford Pharmaceuticals, Inc. | Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity |
| FR2776291B1 (fr) * | 1998-03-18 | 2000-06-16 | Pf Medicament | Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament |
| US6395749B1 (en) | 1998-05-15 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, methods, and compositions for inhibiting PARP activity |
| US6380193B1 (en) | 1998-05-15 | 2002-04-30 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds, methods and compositions for inhibiting PARP activity |
| EP1077946A1 (de) * | 1998-05-15 | 2001-02-28 | Guilford Pharmaceuticals Inc. | Kondensierte trizkylische verbindungen, die parp hemmen |
| EP1077944A1 (de) * | 1998-05-15 | 2001-02-28 | Guilford Pharmaceuticals Inc. | Carboxamide verbindungen,methode und zusammensetzungen zur hemmung derparp-aktivitaet |
| DK1143954T3 (da) | 1998-12-01 | 2004-12-20 | Univ Kentucky Res Found | Anvendelse af nicotinsyrederivater til behandling af DNA-skade i hudceller |
| US6201020B1 (en) | 1998-12-31 | 2001-03-13 | Guilford Pharmaceuticals, Inc. | Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp |
| US6387902B1 (en) | 1998-12-31 | 2002-05-14 | Guilford Pharmaceuticals, Inc. | Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP |
| PL210415B1 (pl) | 1999-01-11 | 2012-01-31 | Agouron Pharma | Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu |
| ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
| US7230000B1 (en) | 1999-10-27 | 2007-06-12 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| US6444676B1 (en) | 1999-12-20 | 2002-09-03 | Iok-Hou Pang | Use of PARP inhibitors in the treatment of glaucoma |
| US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| SI2223922T1 (sl) | 2000-04-25 | 2016-04-29 | Icos Corporation | Inhibitorji humane fosfatidil-inositol 3-kinazne delta izoforme |
| US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
| US6723733B2 (en) | 2000-05-19 | 2004-04-20 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses |
| AU2001275085A1 (en) | 2000-06-01 | 2001-12-11 | Guilford Pharmaceuticals Inc. | Methods, compounds and compositions for treating gout |
| AU2001273099A1 (en) | 2000-07-13 | 2002-01-30 | Guilford Pharmaceuticals Inc. | Substituted 4,9-dihydrocyclopenta(imn) phenanthridine-5-ones, derivatives thereof and their uses |
| GB0017508D0 (en) * | 2000-07-17 | 2000-08-30 | Novartis Ag | Antimicrobials |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| US6660858B2 (en) | 2001-03-28 | 2003-12-09 | Lion Bioscience Ag | 2-aminobenzoxazole derivatives and combinatorial libraries thereof |
| CN1568187A (zh) * | 2001-08-15 | 2005-01-19 | Icos股份有限公司 | 2h－2,3－二氮杂萘－1－酮和其使用方法 |
| AU2002346471A1 (en) | 2001-11-20 | 2003-06-10 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
| AUPR975601A0 (en) * | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
| AUPS019702A0 (en) * | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| AU2003213092A1 (en) | 2002-02-15 | 2003-09-09 | Smithkline Beecham Corporation | Syntheses of quinazolinones |
| AU2003229953A1 (en) | 2002-04-30 | 2003-11-17 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| WO2003094839A2 (en) | 2002-05-09 | 2003-11-20 | Cytokinetics, Inc. | Pyrimidinone compounds, compositions and methods |
| US7214800B2 (en) | 2002-05-09 | 2007-05-08 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| AU2003265242A1 (en) | 2002-05-23 | 2003-12-22 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| WO2003106426A1 (en) | 2002-06-14 | 2003-12-24 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| WO2004009036A2 (en) | 2002-07-23 | 2004-01-29 | Cytokinetics, Inc. | Compounds compositions and methods |
| AU2003262747A1 (en) * | 2002-08-21 | 2004-03-11 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| US7557115B2 (en) | 2002-09-30 | 2009-07-07 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| AU2002951868A0 (en) * | 2002-10-04 | 2002-10-24 | Prana Biotechnology Limited | Compound i |
| DK1558585T3 (da) | 2002-10-04 | 2014-01-06 | Prana Biotechnology Ltd | Neurologisk aktive forbindelser |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| BRPI0408996A (pt) * | 2003-03-31 | 2006-03-28 | Pfizer | saia de inibidores tricìclicos de poli(adpp-ribose) polimerases |
| GB0317466D0 (en) * | 2003-07-25 | 2003-08-27 | Univ Sheffield | Use |
| WO2005041888A2 (en) * | 2003-11-03 | 2005-05-12 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions and methods |
| JP2007510660A (ja) * | 2003-11-07 | 2007-04-26 | サイトキネティクス・インコーポレーテッド | 化合物、組成物及び方法 |
| EP1709011B1 (de) | 2003-11-20 | 2015-07-29 | Janssen Pharmaceutica NV | 7-phenylalkylsubstituierte 2-chinolinone und 2-chinoxalinone als inhibitoren von poly(adp-ribose)polymerase |
| KR101118582B1 (ko) | 2003-11-20 | 2012-02-27 | 얀센 파마슈티카 엔.브이. | 폴리(ａｄｐ-리보스)폴리머라제 저해제로서의 6-알케닐 및6-페닐알킬 치환된 2-퀴놀리논 및 2-퀴녹살리논 |
| JP5545690B2 (ja) | 2003-12-01 | 2014-07-09 | クドス ファーマシューティカルズ リミテッド | 癌治療のためのｄｎａ損傷修復阻害剤 |
| US7439254B2 (en) | 2003-12-08 | 2008-10-21 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| ES2605792T3 (es) | 2004-05-13 | 2017-03-16 | Icos Corporation | Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana |
| EA014955B1 (ru) | 2004-06-30 | 2011-04-29 | Янссен Фармацевтика Н. В. | Производные фталазина в качестве ингибиторов parp |
| UA85593C2 (uk) | 2004-06-30 | 2009-02-10 | Янссен Фармацевтика Н.В. | Похідні хіназолінону як інгібітори parp |
| MXPA06014541A (es) | 2004-06-30 | 2007-03-23 | Janssen Pharmaceutica Nv | Derivados de quinazolindiona como inhibidores de la poli(adp-ribosa) polimerasa. |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| CN100431606C (zh) * | 2004-11-22 | 2008-11-12 | 山东蓝金生物工程有限公司 | 一种抗癌药物组合物 |
| GB0428111D0 (en) * | 2004-12-22 | 2005-01-26 | Kudos Pharm Ltd | Pthalazinone derivatives |
| CA2602854C (en) | 2005-04-01 | 2013-05-14 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US20070015814A1 (en) * | 2005-06-10 | 2007-01-18 | Ernest Kun | Parp Modulators and Treatment of Cancer |
| CN101242822B (zh) * | 2005-07-18 | 2011-08-24 | 彼帕科学公司 | 治疗卵巢癌的药物 |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| CA2629376C (en) * | 2005-11-14 | 2015-06-09 | Centre National De La Recherche Scientifique - Cnrs | Inhibitors of parp activity and uses thereof |
| US8560350B2 (en) * | 2005-11-22 | 2013-10-15 | Robert J. Nadai | Method, system and computer program product for generating an electronic bill having optimized insurance claim items |
| US20140039920A1 (en) * | 2005-11-22 | 2014-02-06 | Robert J. Nadai | Methodology, system and computer program product for generating electronic insurance claims or bills, having optimized insurance claim items in order to maximize reimbursement and to facilitate approval of the claim(s) upon first submission to the insurance carrier |
| NZ590271A (en) | 2006-04-14 | 2011-12-22 | Prana Biotechnology Ltd | 9-hydroxy-3-substituted-4H-pyrido[1,2-a]pyrimidin-4-ones and 9-hydroxy-3-substituted-4H-pyrido[1,2-a]pyrimidin-4-thiones |
| US8481529B2 (en) * | 2006-05-16 | 2013-07-09 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Combination cancer chemotherapy |
| US20080262062A1 (en) * | 2006-11-20 | 2008-10-23 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| AU2007354301A1 (en) * | 2006-06-12 | 2008-12-04 | Bipar Sciences, Inc. | Method of treating diseases with PARP inhibitors |
| US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
| US20090209520A1 (en) * | 2006-06-15 | 2009-08-20 | Kudos Pharmaceuticals Limited | 2 -oxybenzamide derivatives as parp inhibitors |
| US7994222B2 (en) * | 2006-09-05 | 2011-08-09 | Bipar Sciences, Inc. | Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds |
| WO2008030883A2 (en) * | 2006-09-05 | 2008-03-13 | Bipar Sciences, Inc. | Treatment of cancer |
| TWI404716B (zh) | 2006-10-17 | 2013-08-11 | Kudos Pharm Ltd | 酞嗪酮（ｐｈｔｈａｌａｚｉｎｏｎｅ）衍生物 |
| AR064777A1 (es) | 2007-01-10 | 2009-04-22 | Inst Di Reserche D Biolog Mole | Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp) |
| AU2008223793B2 (en) | 2007-03-08 | 2012-08-23 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP and TANK inhibitors |
| CN101809017A (zh) | 2007-09-14 | 2010-08-18 | 阿斯利康(瑞典)有限公司 | 酞嗪酮衍生物 |
| WO2009053373A1 (en) | 2007-10-26 | 2009-04-30 | Janssen Pharmaceutica Nv | Quinolinone derivatives as parp inhibitors |
| AU2008321128A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| MX2010005221A (es) * | 2007-11-12 | 2010-09-28 | Bipar Sciences Inc | Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales. |
| US20090149397A1 (en) * | 2007-12-07 | 2009-06-11 | Bipar Sciences | Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors |
| CN101932572A (zh) | 2008-01-08 | 2010-12-29 | 默沙东有限公司 | 2-{4-[(3s)-哌啶-3-基]苯基}-2h-吲唑-7-羧酰胺的药学可接受的盐 |
| AR070221A1 (es) | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| US20090275608A1 (en) * | 2008-02-04 | 2009-11-05 | Bipar Sciences, Inc. | Methods of diagnosing and treating parp-mediated diseases |
| WO2009099736A2 (en) * | 2008-02-06 | 2009-08-13 | Lead Therapeutics, Inc. | Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp) |
| CN101531638B (zh) * | 2008-03-13 | 2011-12-28 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| US8889866B2 (en) | 2008-03-27 | 2014-11-18 | Janssen Pharmaceutica, Nv | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors |
| WO2009118384A1 (en) | 2008-03-27 | 2009-10-01 | Janssen Pharmaceutica Nv | Quinazolinone derivatives as tubulin polymerization inhibitors |
| CN101628913B (zh) * | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
| ME02640B (de) | 2008-10-07 | 2017-06-20 | Kudos Pharm Ltd | Pharmazeutische formulierung 514 |
| CN102271683B (zh) | 2008-11-13 | 2014-07-09 | 吉里德卡利斯托加公司 | 恶性血液病的治疗 |
| US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
| WO2010082813A1 (en) | 2009-01-13 | 2010-07-22 | Academisch Medisch Centrum Bij De Universiteit Van Amsterdam | Method of treating cancer |
| WO2010083220A1 (en) | 2009-01-19 | 2010-07-22 | Abbott Laboratories | Benzoxazole inhibitors of poly(adp-ribose)polymerase |
| SG174529A1 (en) | 2009-03-24 | 2011-10-28 | Gilead Calistoga Llc | Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
| KR20120005523A (ko) | 2009-04-20 | 2012-01-16 | 길리아드 칼리스토가 엘엘씨 | 고형 종양의 치료 방법 |
| MX2012000817A (es) | 2009-07-21 | 2012-05-08 | Gilead Calistoga Llc | Tratamiento para desordenes del higado con inhibidores pi3k. |
| WO2011058367A2 (en) | 2009-11-13 | 2011-05-19 | Astrazeneca Ab | Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor |
| EP2611300B1 (de) * | 2010-09-03 | 2016-04-06 | Bayer Intellectual Property GmbH | Substituierte anellierte dihydropyrimidinonderivate |
| CN102382097B (zh) * | 2010-09-03 | 2013-08-07 | 中国科学院上海药物研究所 | 芳甲胺类衍生物及其药物组合物、制备方法和用途 |
| US9102631B2 (en) * | 2011-11-01 | 2015-08-11 | Impact Therapeutics, Inc. | 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof |
| CN102531946A (zh) * | 2012-01-05 | 2012-07-04 | 山东大学 | 3-甲氧基苯甲酰胺衍生物及其制备方法与应用 |
| CA2864305C (en) | 2012-03-05 | 2021-02-16 | Gilead Calistoga Llc | Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one |
| EP2892345A1 (de) * | 2012-09-05 | 2015-07-15 | Bayer CropScience AG | Verwendung substituierter 2-amidobenzimidazole, 2-amidobenzoxazole und 2-amidobenzothiazole oder deren salze als wirkstoffe gegen abiotischen pflanzenstress |
| EP2900643B1 (de) * | 2012-09-26 | 2017-09-27 | Merck Patent GmbH | Quinazolinone derivate als parp inhibitoren |
| ES2752552T3 (es) | 2013-12-20 | 2020-04-06 | Gilead Calistoga Llc | Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa |
| JP2017500319A (ja) | 2013-12-20 | 2017-01-05 | ギリアード カリストガ エルエルシー | （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態 |
| EP3689420A1 (de) * | 2014-01-23 | 2020-08-05 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Icariin-derivate zur anwendung in einem verfahren zur behandlung von myelodysplastischem syndrom |
| NZ726360A (en) | 2014-06-13 | 2018-04-27 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
| EP3265560B1 (de) | 2015-03-02 | 2021-12-08 | Sinai Health System | Homologe rekombinationsfaktoren |
| ES2742197T7 (es) | 2015-07-23 | 2021-10-06 | Inst Curie | Uso de una combinación de molécula Dbait e inhibidores de PARP para tratamiento del cáncer |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| US10874641B2 (en) | 2016-07-28 | 2020-12-29 | Mitobridge, Inc. | Methods of treating acute kidney injury |
| MA46779A (fr) | 2016-11-02 | 2019-09-11 | Health Research Inc | Traitement combiné avec des conjugués anticorps-médicament et des inhibiteurs de parp |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| EP3615026B1 (de) | 2017-04-28 | 2021-03-03 | Akribes Biomedical GmbH | Ein parp-hemmer in kombination mit einem glucocorticoid und/oder ascorbinsäure und/oder einem proteinwachstumsfaktor zur behandlung von gestörter wundheilung |
| EP3765613A1 (de) | 2018-03-13 | 2021-01-20 | Onxeo | Dbait-molekül gegen erworbene resistenz in der behandlung von krebs |
| EP3860988A1 (de) | 2018-10-03 | 2021-08-11 | Tesaro, Inc. | Kristalline formen der freien base von nirapaib |
| KR20220030256A (ko) * | 2019-07-01 | 2022-03-10 | 아센타위츠 파마슈티컬즈 리미티드 | Akr1c3 저해제 및 이의 의학적 용도 |
| GB201913030D0 (en) | 2019-09-10 | 2019-10-23 | Francis Crick Institute Ltd | Treatment of hr deficient cancer |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2024261243A1 (en) | 2023-06-21 | 2024-12-26 | Hemispherian As | Combination comprising a deoxycytidine derivative and a parp inhibitor for use in a method of treating hr proficient cancer |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US26565A (en) * | 1859-12-27 | Improved register for railroad-cars | ||
| US3169129A (en) * | 1963-05-10 | 1965-02-09 | American Cyanamid Co | 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones |
| USRE26565E (en) | 1966-03-02 | 1969-04-29 | Table iii | |
| GB1338235A (en) * | 1970-12-15 | 1973-11-21 | May & Baker Ltd | Azapurinones |
| US4323503A (en) * | 1976-08-04 | 1982-04-06 | Societe D'etudes Scientifiques Et Industrielles De L'ile-De-France | Substituted 2,3-alkylene di (oxy) benzamides and derivatives |
| US4281127A (en) * | 1979-07-09 | 1981-07-28 | Hoffmann-La Roche Inc. | Trans-3-(4-oxo-4H-quinazolin-3-yl)-2-propenoic acid derivatives |
| DE3166627D1 (en) * | 1980-12-12 | 1984-11-15 | Thomae Gmbh Dr K | Pyrimidones, their preparation and medicines containing them |
| DE3202898A1 (de) | 1982-01-29 | 1983-08-11 | Geze Gmbh, 7250 Leonberg | Antriebseinheit fuer fluegel, insbesondere schiebefluegel von tueren o.dgl. |
| DE3220898A1 (de) * | 1982-06-03 | 1983-12-08 | Dr. Karl Thomae Gmbh, 7950 Biberach | Verfahren zur herstellung von pyrimidinonen und ihren saeureadditionssalzen |
| US4499303A (en) * | 1983-09-27 | 1985-02-12 | Research Corporation | Antihyperlipidemic N-benzoylsulfamates, N-benzylsulfamates and benzylsulfonamides |
| WO1986006628A1 (en) * | 1985-05-03 | 1986-11-20 | Sri International | Benzamide and nicotinamide radiosensitizers |
| US5032617A (en) * | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
| JPS62258368A (ja) * | 1986-03-10 | 1987-11-10 | Agency Of Ind Science & Technol | キナゾリン−４−オンの製造方法 |
| EG18188A (en) * | 1986-05-01 | 1992-09-30 | Pfizer Ltd | Process for preparation anti-arhythmia agents |
| ZA885929B (en) * | 1987-08-25 | 1989-04-26 | Oxi Gene Inc | Agents for use in tumor or cancer cell killing therapy |
| CA2020073A1 (en) * | 1989-07-03 | 1991-01-04 | Eric E. Allen | Substituted quinazolinones as angiotensin ii antagonists |
| US5254692A (en) * | 1990-04-06 | 1993-10-19 | Bayer Aktiengesellschaft | 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines |
| GB9011833D0 (en) * | 1990-05-25 | 1990-07-18 | Collins Mary K L | Inhibition of viral infection |
| US5238942A (en) * | 1991-05-10 | 1993-08-24 | Merck & Co., Inc. | Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists |
| DE4142366A1 (de) * | 1991-07-15 | 1993-06-24 | Thomae Gmbh Dr K | Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| AU676992B2 (en) * | 1991-10-22 | 1997-04-10 | Emory University | Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as anti-tumor and anti-retroviral agents |
| US5464871A (en) * | 1993-05-12 | 1995-11-07 | Octamer, Inc. | Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents |
| US5223539A (en) * | 1991-11-22 | 1993-06-29 | G. D. Searle & Co. | N,n-di-alkyl(phenoxy)benzamide derivatives |
| GB9126260D0 (en) * | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
| US5587384A (en) * | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
-
1994
- 1994-03-09 GB GB9404485A patent/GB9404485D0/en active Pending
-
1995
- 1995-03-09 DE DE69524641T patent/DE69524641T2/de not_active Expired - Fee Related
- 1995-03-09 DK DK98202102T patent/DK0879820T3/da active
- 1995-03-09 EP EP95910653A patent/EP0749415B1/de not_active Expired - Lifetime
- 1995-03-09 AT AT98202103T patent/ATE231494T1/de not_active IP Right Cessation
- 1995-03-09 DE DE69512036T patent/DE69512036T2/de not_active Expired - Fee Related
- 1995-03-09 ES ES95910653T patent/ES2135707T3/es not_active Expired - Lifetime
- 1995-03-09 CN CN95192011A patent/CN1081624C/zh not_active Expired - Fee Related
- 1995-03-09 DK DK95910653T patent/DK0749415T3/da active
- 1995-03-09 EP EP98202102A patent/EP0879820B1/de not_active Expired - Lifetime
- 1995-03-09 WO PCT/GB1995/000513 patent/WO1995024379A1/en not_active Ceased
- 1995-03-09 AT AT95910653T patent/ATE184271T1/de not_active IP Right Cessation
- 1995-03-09 JP JP7523316A patent/JPH09510704A/ja active Pending
- 1995-03-09 PT PT98202102T patent/PT879820E/pt unknown
- 1995-03-09 DE DE69529482T patent/DE69529482T2/de not_active Expired - Fee Related
- 1995-03-09 EP EP98202103A patent/EP0897915B1/de not_active Expired - Lifetime
- 1995-03-09 AT AT98202102T patent/ATE210651T1/de not_active IP Right Cessation
- 1995-03-09 ES ES98202102T patent/ES2169472T3/es not_active Expired - Lifetime
- 1995-03-09 CA CA002184747A patent/CA2184747C/en not_active Expired - Fee Related
-
1996
- 1996-08-30 US US08/706,326 patent/US5756510A/en not_active Expired - Fee Related
-
1998
- 1998-04-08 US US09/056,928 patent/US6015827A/en not_active Expired - Fee Related
-
1999
- 1999-11-18 GR GR990402976T patent/GR3031886T3/el unknown
- 1999-11-24 US US09/448,485 patent/US6316455B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6015827A (en) | 2000-01-18 |
| DK0879820T3 (da) | 2002-04-02 |
| US5756510A (en) | 1998-05-26 |
| DE69512036D1 (de) | 1999-10-14 |
| DE69524641T2 (de) | 2002-08-14 |
| AU1856595A (en) | 1995-09-25 |
| DE69529482D1 (de) | 2003-02-27 |
| EP0879820A1 (de) | 1998-11-25 |
| EP0897915A1 (de) | 1999-02-24 |
| DK0749415T3 (da) | 2000-03-20 |
| EP0897915B1 (de) | 2003-01-22 |
| EP0749415B1 (de) | 1999-09-08 |
| US6316455B1 (en) | 2001-11-13 |
| ES2169472T3 (es) | 2002-07-01 |
| ATE210651T1 (de) | 2001-12-15 |
| DE69529482T2 (de) | 2003-06-12 |
| WO1995024379A1 (en) | 1995-09-14 |
| GR3031886T3 (en) | 2000-02-29 |
| JPH09510704A (ja) | 1997-10-28 |
| CA2184747A1 (en) | 1995-09-14 |
| DE69512036T2 (de) | 1999-12-30 |
| EP0879820B1 (de) | 2001-12-12 |
| GB9404485D0 (en) | 1994-04-20 |
| AU693167B2 (en) | 1998-06-25 |
| CN1143358A (zh) | 1997-02-19 |
| CN1081624C (zh) | 2002-03-27 |
| ATE184271T1 (de) | 1999-09-15 |
| PT879820E (pt) | 2002-06-28 |
| EP0749415A1 (de) | 1996-12-27 |
| CA2184747C (en) | 2003-10-14 |
| DE69524641D1 (de) | 2002-01-24 |
| ES2135707T3 (es) | 1999-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE231494T1 (de) | Chinazoline als chemotherapeutika | |
| DE60218458D1 (de) | Isochinolinon derivate als parp inhibitoren | |
| TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
| ATE223424T1 (de) | Quinazolinon-verbindungen | |
| EA199800184A1 (ru) | Соединение бензимидазола | |
| BR0010342A (pt) | Composto, droga, e, uso de composto da fórmula i ou ii | |
| AU2003301020A1 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
| NO2013002I1 (no) | Aklidinium haogenid (Aklidinium bromid) | |
| AU4327600A (en) | Aryl sulfonyls as factor xa inhibitors | |
| BR0007527A (pt) | Fenilfenantridinas com atividade inibitória depde-iv | |
| ATE197401T1 (de) | Chinazolinon-arzneimittel sowie deren verwendung | |
| DK1042319T3 (da) | Dihydrobenzofuraner | |
| PT1098885E (pt) | Compostos de imidazole e sua utilizacao como inibidores da desaminase de adenosina | |
| WO2003051276A3 (en) | Therapeutic heterocycles | |
| NO20023175L (no) | Kamptotecin beta-alaninestere med topoisomerase I inhibering | |
| PT1245564E (pt) | Derivados de benzamidina. | |
| CA2352592A1 (en) | Quinazolinone compounds | |
| SI0937075T1 (en) | New Imidazo- and Oxazolopyridines as Phosphodiesterase Inhibitors. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |